Post Covid Conditions

2

Review clinical trials related to Post Covid Conditions. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19

Fatigue, cognitive problems, post-exertional malaise (PEM) and postural orthostatic tachycardia syndrome (POTS) are common and debilitating symptoms after COVID-19. The pathophysiology of post-COVID is not well understood and there is no established biomedical treatment. Treatment options for post-COVID are thus much needed. A promising candidate intervention is fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), that may reduce post-COVID symptoms because of its regulatory effect on the (neuro) immune system, the hypothalamic-pituitary-adrenal (HPA) axis and the tryptophan system. The investigators will randomize 160 participants to either fluvoxamine or placebo for 12 weeks. The investigators will use advanced functional neuroimaging techniques during cognitive challenge (optional substudy) and plasma biomarkers (inflammatory markers, cortisol, serotonin, IDO-2 activity), to facilitate identifying potential mechanistic pathways of post -COVID treatment.

Participants needed: 160
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Updated: Jun 9, 2026Locations: 1
Eligibility criteria

Adults aged 18 to 70 years [+8]

Use of medication with interaction with fluvoxamine that cannot be discontinued [+16]

Status: Recruiting

Modifying Adiposity Through Behavioral Strategies to Improve COVID-19 Rehabilitation

The research in this VA Merit will examine the effects of obesity and Post-COVID Conditions (PCC) on physical functioning, health-related quality of life, and adipose tissue inflammatory and cellular senescence profiles in older Veterans. Further, it will evaluate whether a weight loss intervention, including dietary modification and exercise, in obese Veterans with and without PCC will reduce systemic and adipose tissue inflammation and senescence and promote PCC recovery.

Participants needed: 150
Trial details
Age: Up to 80Biological sex: AllType: InterventionalSponsor: VA Office of Research and DevelopmentUpdated: Jun 1, 2026Locations: 2
Eligibility criteria

U.S. Veteran [+2]

Neurologic, musculoskeletal, or other condition that limits subject's ability to... [+5]